Site Map
AzurRx
- Interviews-test
- Home
- About
- Science & Technology
- Investors
- AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial
- AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting
- AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20)
- AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference
- Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights
- AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial
- AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference
- AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial
- AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers
- AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
- AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET
- AzurRx BioPharma Announces Proposed Public Offering of Common Stock
- AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock
- AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients
- AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer
- AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
- AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data
- AzurRx BioPharma CEO Issues Letter to Shareholders
- AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
- Press Releases
- AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer
- AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)
- AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco
- AzurRx BioPharma Announces Closing of $6.9 Million Private Placement
- AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference
- AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit)
- AzurRx BioPharma to Present at the New York City based Investor Summit on March 25th-26th
- AzurRx BioPharma Receives $642,000 for its 2017 CIR (French Research Tax Credit)
- AzurRx Appoints Gregory Oakes to its Board of Directors
- AzurRx BioPharma to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020
- AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product
- Argus Research Initiates Equity Research Report Coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX)
- AzurRx BioPharma Issues Letter to Shareholders
- AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites
- AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
- AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)
- AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product
- AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange
- AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites Activated
- AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
- AzurRx BioPharma CEO Issues Clarifying Statement to Shareholders
- AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
- AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
- AzurRx BioPharma to Present at The LD 500 Virtual Conference (September 4th)
- AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)
- AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference
- 2018
- AzurRx BioPharma Receives $2 Million in Proceeds from Exercise of Warrants
- AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic Insufficiency
- AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th)
- AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD
- AzurRx BioPharma to Present at the 30th Annual ROTH Conference (March 12th)
- AzurRx BioPharma Announces Positive Preclinical Data with AZX1103
- AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI)
- AzurRx BioPharma Announces Proposed Public Offering of Common Stock
- AzurRx BioPharma Announces Pricing of $10.4 Million Public Offering of Common Stock
- AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer
- AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency
- AzurRx BioPharma to Present at the 2018 Cannacord Genuity 38th Annual Growth Conference (August 9th)
- AzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 5th
- AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis
- AzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
- AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI
- AzurRx BioPharma to Present at the 11th Annual LD Micro Main Event
- AzurRx BioPharma to Present at Upcoming Investor Conferences
- AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group
- AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
- 2017
- AzurRx Announces Addition of Charles J Casamento to the Board of Directors
- AzurRx Provides Update on MS1819 Phase II Trial
- AzurRx BioPharma to Present at the 2017 LD Micro Invitational Conference (June 6) and the 2017 Marcum MicroCap Conference (June 15)
- AzurRx BioPharma Announces Closing of $5.0 Million Private Financing
- AzurRx Reaches 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of Exocrine Pancreatic Insufficiency Associated with Chronic Pancreatitis
- AzurRx BioPharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 12
- AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer
- AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)
- AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors
- AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission
- AzurRx BioPharma to Present at the 2017 LD Micro 10th Annual Main Event Conference (December 5th)
- AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th)
- AzurRx BioPharma Announces Publication of U.S. Patent Application for AZX1101
- 2016
- AzurRx BioPharma Announces Pricing of Initial Public Offering
- AzurRx BioPharma Inc. (Nasdaq: AZRX) to Ring The Nasdaq Stock Market Closing Bell
- AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients
- AzurRx BioPharma to Present at the 9th Annual LD Micro Main Event
- AzurRx CEO Provides Shareholders With a "State of the Union" Communication
- AzurRx BioPharma Announces Agreement in Principle with TransChem for MTAN Inhibition Technology
- WallachBeth Capital Initiates Research Coverage of AzurRx BioPharma
- AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Exocrine Pancreatic Insufficiency
- AzurRx BioPharma to Present at the 2017 Biotech Showcase Conference
- 2015
- 2014
- Events
- Presentation
- Regulatory Filings
- Financial Statements
- 2019
- 2018
- 2017
- 2016
- Stock Info
- Analyst Coverage
- Corporate Governance
- Investor Relations
- Contact Us
- MS1819 R&D Update (July 2019)
- Clinical Trials
- MS1819 Research to Date Demonstrates Safety and Supports Efficacy
- Ongoing Clinical Trials
- Clinical Publications
- A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
- Impact of a spray dried recombinant lipase, MS1819, For the treatment of exocrine pancreatic insufficiency in patients with chronic pancreatitis. Results of a multicenter, Phase II, open-label, non-randomized study
- Yarrowia lipolytica Lipase 2 is Stable and Highly Active in Test Meals and Increases Fat Absorption in an Animal Model of Pancreatic Exocrine Insuffiency.
- Collaborations
- News Feed
- Interview
- Interviews
- testhome